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Pluripotent stem cells can diﬀerentiate into various lineages but undergo genetic and epigenetic changes during long-term
cultivation and, therefore, require regular monitoring. The expression patterns of cancer-testis antigens (CTAs) MAGE-A2,
-A3, -A4, -A6, -A8, -B2, and GAGE were examined in undiﬀerentiated human embryonic stem (hES) cells, their diﬀerentiated
derivatives, teratocarcinoma (hEC) cells, and cancer cell lines of neuroectodermal and mesodermal origin. Undiﬀerentiated hES
cells and embryoid body cells expressed MAGE-A3, -A6, -A4, -A8, and GAGEs while later diﬀerentiated derivatives expressed
only MAGE-A8 or MAGE-A4. Likewise, mouse pluripotent stem cells also express CTAs of Magea but not Mageb family. Despite
similarity of the hES and hEC cell expression patterns, MAGE-A2 and MAGE-B2 were detected only in hEC cells but not in hES
cells.Moreover,ouranalysishasshownthatCTAsareaberrantlyexpressedincancercelllinesanddisplaylowtissuespeciﬁcity.The
identiﬁcation of CTA expression patterns in pluripotent stem cells and their derivatives may be useful for isolation of abnormally
CTA-expressing cells to improve the safety of stem-cell based therapy.
1.Introduction
Two approaches for pluripotent stem cell line production
have been developed. The traditional way consists in the iso-
lation of pluripotent cells from preimplantation embryos or
the conversion of embryonic germ line cells into pluripotent
stem cells [1–4]. Another approach is experimental genome
reprogramming of somatic cells to change their diﬀerenti-
ation potential. There are three technologies of reprogram-
ming: somatic cell nuclear transfer, fusion of pluripotent and
somatic cells, and induction of pluripotency in somatic cells
by introduction of pluripotency-related genes or proteins
[5–7]. Despite diﬀerent origin, all pluripotent stem cell
lines display considerable similarity of the basic biological
properties: high self-renewal rate and ability of in vitro and
in vivo diﬀerentiation into a wide variety of cell types. On
the other hand, comparative analysis of numerous derived
human embryonic stem (hES) cell lines demonstrated that
they diﬀered in cell growth rate, gene expression proﬁles,
gene methylation proﬁles, and microRNA proﬁles [8–10].
These diﬀerences may be due to the genetic background of
pluripotent embryonic cells initiating hES cell lines, diﬀerent
culturesystemsusedfortheirmaintenanceaswellasstochas-
tic events during long-term in vitro cultivation which lead to
genomic alterations [11–14]. Moreover, induced pluripotent
stem (iPS) cells derived from diﬀerent somatic cells diﬀer in
theirdiﬀerentiationandtumorigenicpotentials[15–17].The
variation of transcriptional and gene methylation proﬁles of
human ES and iPS cell lines has been widely discussed [18–
24].
Numerousstudieshaveshownthatlong-termcultivation
leadstotheaccumulationofdiﬀerentgeneticaberrationsand
abnormal epigenetic changes by the pluripotent stem cells,
and such changes can contribute to genomic instability, cell2 Stem Cells International
transformation, and cancer development [11, 13, 25, 26].
Furthermore, most iPS cell lines were generated by overacti-
vation of cell oncogenes C-Myc and Klf4 that might enhance
their spontaneous uncontrolled expression in undiﬀerenti-
ated pluripotent stem cells and in diﬀerentiating progenitor
cells, and, therefore, these cells may be transformed to cancer
stemcells[27].Takentogether,allthesedataindicatethatuti-
lized pluripotent stem cell lines require regular monitoring
of genetic and epigenetic integrity. In addition, large-scale
searching of new gene markers is required for identiﬁcation
of the cells that underwent tumorigenic transformation.
Cancer-testis-associated antigens (CTAs) may be consid-
ered as potential gene candidates speciﬁc for transformed
cells because they are frequently expressed in diﬀerent types
of cancers but have very restricted expression patterns in
normal tissues [28] .A l lC T A sh a v eb e e ns h o w nt ob ee x -
pressed in male gonads, some of them are expressed in the
trophoblast,placenta,anddevelopingcentralnervoussystem
[29–33]. Several gene families are ubiquitously expressed in
s o m a t i ca n dg e r mc e l l sa sw e l la si nc a n c e rc e l l s[ 30]. In
addition, certain CTAs were detected in the mesenchymal
stem cells and diﬀerentiated hES cells [29, 34]. However, cell
functions ofmost CTA families which include more than 100
genes remain enigmatic. Recent studies have demonstrated
that CTAs are involved in the regulation of transcription
[35], cell cycle and proliferation [36–39], apoptosis [40],
and susceptibility to cytokines in cancer cells [41]. Moreover,
the expression of some CTAs including MAGEA, SSX, and
NY-ESO families is regulated epigenetically by promoter
methylation and histone acetylation mechanisms [42–44]. A
subset of CTA proteins has been found to elicit spontaneous
humoral and cytotoxic T-cell-mediated immune responses
in cancer patients, and, therefore, these antigens could be
potential cancer vaccine targets [28, 45, 46].
On the other hand, CTAs may be involved in the speci-
ﬁcation of the early embryonic lineages. MAGEA and GAGE
families have been demonstrated to be expressed speciﬁcally
in the human germ line during the development of male
and female reproductive systems [47–50]. In order to clarify
the possible role of CTAs in lineage determination during
early development and speciﬁcity of CTA expression during
pathological tissue development, we have examined CTA
expression patterns of MAGE A, B, D, and GAGE families in
the pluripotent stem cells, their spontaneously diﬀerentiated
cell derivatives, and cancer cell lines derived from tissues of
neuroectodermal and mesodermal origin.
2.MaterialsandMethods
2.1. Cell Lines. We utilized hES cell lines SC5, SC7, and
SC3a derived from blastocysts (Institute of Cytology, Rus-
sian Academy of Sciences, St. Petersburg) [51]. Mouse
ES cell R1 line was kindly provided by A. Nagy (Mount
Sinai Hospital, Toronto, Canada), mouse embryonic germ
cell (EG) line EGC-10 derived from E10.5 embryos was
provided by A. McLaren (WTCR Institute of Cancer and
Developmental Biology, Cambridge, UK). All cancer cell
lines were obtained from Russian Cell Culture Collection
(http://www.rccc.cytspb.rssi.ru/). The following groups of
cancer cell lines were used: (1) human teratocarcinoma PA-1
and mouse teratocarcinoma F9, (2) human neuroblastomas
IMR-32 and SK-N-MC, (3) human glioblastomas A-172,
GL-6 (U-251MG), T-98G, (4) human rhabdomyosarcoma
A-204v and embryonal rhabdomyosarcoma RD, and (5)
human osteosarcoma HOS (TE85, clone F5),MG-63, U-2
OS.
2.2. Human Tissue Specimens. The human tissue samples of
testes and brains were obtained from adult males during
postmortem examination in Forensic Medical Examina-
tion Bureau, Moscow Department of Public Health. The
procedures of human tissue sampling were carried out
according to the Funeral Law of Russian Federation and
were approved by the Institutional Ethics Committee. After
autopsy, the tissue samples were immediately transferred to
TRIzol Reagent (Invitrogen).
2.3. Mouse Embryos and Tissues Sampling. C57Bl/6 mice at
the age of 2-3 months were obtained from the Animal Breed-
ing Facility-Branch “Pushchino” (Institute of Bioorganic
Chemistry, Russian Academy of Sciences). Animal keeping
and experiments were approved by the Institutional Ethics
Committee. Total RNAs were extracted from E 7.5 mouse
embryos with removed placenta, fetal gonads associated with
attached mesonephros of E11.5 embryos, and male fetal
gonads from E14.5 embryos. In addition, total RNAs were
isolatedfromtesticleandbraintissuesamplesofadultmouse
males.
2.4. Cell Line Maintenance. Human ES cell lines were main-
tained on human embryonic ﬁbroblast feeder cells (Rus-
sian Cell Culture Collection of Vertebrates at the Insti-
tute of Cytology) inactivated by mitomycin C treat-
ment (10ug/mL, Sigma). ES cells and their diﬀerentiated
cell derivatives were cultivated in KnockOut Dulbecco’s
modiﬁed Eagle’s medium (KDMEM) supplemented with
2mM L-glutamine, 1% nonessential amino acids, 10ng/mL
basic ﬁbroblast growth factor bFGF (Invitrogen), 0.1mM
β-mercaptoethanol (Sigma), and 15% Knockout Serum
Replacement (Gibco/Invitrogen). Colonies of undiﬀerenti-
ated hES cells were manually detached from the feeder cells,
divided into cell clusters and transferred into low adhesion
cultureplatesfor spheroid generation or into new plates with
feeder cells for following expanding. After isolation from the
feeder cells, the hES cell clusters formed embryoid bodies
(EBs) within one day of cultivation into low adhesion plates
(Greiner Bio-one). At day 10 of cultivation in nonadherent
culture, EBs were collected and used for RT-PCR analysis.
The early cell derivatives of hES SC5 or SC7 cells have
been isolated from spontaneously diﬀerentiated adherent
ES cell cultures maintained without feeder cells for 10–
14 days in the hES cell media. Uniform cell outgrowths
of extraembryonic endoderm, early neuroectodermal-like
rosette structures and mesenchymal-like cells were isolated
manually, propagated under feeder-free conditions, and
collected for RT-PCR and immunohistochemical analyses.Stem Cells International 3
Mouse ES and EG cells were maintained on mouse
embryonal ﬁbroblast feeder cells inactivated by mitomycin
C or in a feeder-free system in media containing leukemia
inhibitory factor (LIF, 10ng/mL). Mouse ES and EG cells,
mouse teratocarcinoma F9 and human teratocarcinoma PA-
1 cells were cultivated in DMEM supplemented with 2mM
L-glutamine, 1% nonessential amino acids, (HyClone),
0.1mMβ-mercaptoethanol(Sigma),and15%Characterized
Fetal Bovine Serum (HyClone). For EB generation R1, EGC-
10, F9, and PA-1 cells were placed in “hanging drops” (500
cellsperdrop)for3days.Afterformation,EBswerecollected
and cultured for 10 days in low adhesion plates.
Neuroblastoma, glioblastoma, rhabdomyosarcoma, and
osteosarcoma cell lines were maintained as recommended
for these cell lines previously (see http://www.rccc.cytspb.rssi
.ru/).
2.5. Teratoma and Teratocarcinoma Assay. For teratoma and
teratocarcinoma to be obtained, we used as recipients
immunodeﬁcient nude mice from the Animal Breeding
Facility-Branch “Pushchino”. All animal study protocols
were approved by the Institutional Bioethical Committee.
Mouse ES, EG, and EC cells and human ES and EC cells
were injected subcutaneously into nude mice (106 cells
per mouse). After tumor development, the animals were
sacriﬁced, teratomas and teratocarcinomas were isolated
and ﬁxed by 10% paraformaldehyde (Sigma), dehydrated
accordingtothestandardmethod,andembeddedintoparaf-
ﬁn for sectioning. Histological preparations were stained
by hematoxylin and eosin and examined under a Leica
DMRXA2 microscope.
Karyotyping. Topreparemetaphasechromosomes,0.1μg/mL
colcemid (Karyomax, Gibco, USA) was added to the culture
media 4h prior to cell ﬁxation. After dissociation, the cells
were treated with hypotonic solution of 0.075M KCl and
1% sodium citrate and then ﬁxed by glacial acetic acid
(3:1). Metaphase spreads were prepared by dropping cells
onto glass slides followed by air drying. Preparations of
metaphase spreads were stained by Giemsa solution. For
the karyotype analysis, routine G-banded technique were
applied.Nolessthan30metaphasespreadsforSC5,SC7,and
SC3a were analysed. The hES cell karyotypes were studied by
an Axio Imager M1 microscope (Carl Zeiss, Germany) with
Ikaros4 Karyotyping System (MetaSystems, Germany) and
described according to the International System for Human
Cytogenetic Nomenclature.
2.6. Detection of Alkaline Phosphatase Activity (ALP) and Im-
munostaining. Human and mouse ES, EG, and EC cells
and EBs were ﬁxed by 2% paraformaldehyde in phosphate-
buﬀered solution, PBS, pH 7.0 within 15min. ALP activity
was detected after incubation in a solution containing 10mL
0,02M Tris-HCl buﬀer (pH 8,7), 1mg Naphtol-AS-B1-
phosphate,and5mgFastReddyeTexasRed(allfromSigma)
at 37◦Cf o r1h .
For immunoﬂuorescence analysis, cells ﬁxed in 4%
paraformaldehydeinPBSfor1hwerewashedandpermeabi-
lized with 0.5% Triton X-100 (Sigma). Nonspeciﬁc reaction
wasblockedby10%chickenserum(Gibco/Invitrogen).Cells
were incubated in a solution of primary antibodies in PBS-
Tween 20 at 4◦C overnight. Primary antibodies rabbit anti-
Oct4, goat anti-GATA4 (Santa Cruz Biotechnology), goat
anti-Nanog (R&D Systems), mouse anti-Nestin (Abcam),
anti-α-Actinin (Sigma), and rabbit anti-BRY (Abcam) were
used in dilution 1:100. Secondary chicken antirabbit, don-
key antigoat, and chicken antimouse antibodies conjugated
withAlexaFluor594andAlexaFluor488(MolecularProbes)
were diluted at 1:900 in blocking buﬀer and applied to
cells for 3h at room temperature. DAPI (Molecular Probes)
was applied for nuclear staining for 20min. Cells were
mounted and examined under a Leica DMRXA2 ﬂuorescent
microscope. For negative controls, primary antibodies were
omitted and the same staining procedure was used.
2.7. RNA Isolation and RT-PCR Analysis. Total RNAs were
extracted from all cell lines, human and mouse tissues, and
mouse embryonic samples using TRIzol Reagent (Invitro-
gen) according to the manufacturer recommendations. Each
sample was treated with TURBO DNase (Ambion/Invitro-
gen) to avoid DNA contamination, and 1μgo ft o t a lR N A
from each sample was reverse transcribed using RevertAid
M-MuLV revertase and random hexamer oligonucleotide
primers (Fermentas) for cDNA synthesis. PCR reaction mix-
tures were prepared according to the manufacturer protocol
for Taq polymerase (Silex). Probes were denaturated at 94◦C
for 5min and cycled at 94◦C for 45s, at 58◦C for 45s, and
at 72◦C for 45s followed by ﬁnal extension at 72◦Cf o r
5min after the completion of 30 cycles. The expression of
housekeeping genes (human RPL19 and mouse Hprt genes)
was used for the normalization of PCR reaction. Primer
sequencesandsizeoftheirexpectedproductsarerepresented
in Tables S1 and S2 (see Supplementary Material available
onlineatdoi:10.4061/2011/745239).PrimerpairforGAGE1,
2, 10, 12, 13 was borrowed from [29].
3. Results
3.1. Expression of CTA Genes in Adult Human and Mouse
Testicular and Brain Tissues. At ﬁrst, we tested the primers
for the detection of CTA expression by RT-PCR in normal
human and mouse tissues used as positive and negative
controls. The expression of MAGE-A2, -A3, -A6, -A4, -
A8, MAGE-B2, MAGE-D1, -D2, and several members of
the GAGE family (GAGE-1, -2, -10, -12, -13) was detected
in human testes whereas only MAGE-D1 and MAGE-D2
were expressed in human brain samples (Figures 1(a)–1(c)).
Likewise, we detected the expression of Mage-a4, Mage-a
1, 2, 3, 5, 6, 8, Mage-b 1-3, Mage-b3, Mage-d1, -d2 in
mouse testes and Mage-d1, -d2 in brains correspondingly
(Figures 1(d) and 1(e)). Our analysis has demonstrated that
all primers detected only PCR sequences of expected size and
did not detect additional nonspeciﬁc sequences. In addition,
the expression of all CTAs studied was detected only in the4 Stem Cells International
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Figure 1: CTA expression in adult human and mouse testicular and brain samples. Designations: T: human testes, B: human brain.
testes whereas in normal somatic tissue (brain samples) only
MAGE-D1, -D2/Mage-d1, -d2 have expressed as expected.
3.2.CTAGeneExpressioninHumanESandECCells. Human
ES cell lines SC5, SC7, and SC3a were recently derived
and characterized as pluripotent stem cells by standard
in vitro and in vivo assays [51] and (Figures 2(a)–2(c)).
The cytogenetic analysis of these cell lines has shown that
they retained normal diploid karyotypes during at least 30
passages: 46, XX for SC5 and SC3a, and 46, XY for SC7
(Figure 2(c)). However, the diﬀerentiation potential of these
lines has been found to be diﬀerent. Human ES cell lines SC5
and SC7 formed teratomas with derivatives of three germ
layers (Figure 2(b)) while SC3a cells were more prone to
diﬀerentiation in vitro and had restricted capacity to grow
in teratomas.
In our experiments, undiﬀerentiated SC5, SC7, and SC3a
cells and EB cells expressed key pluripotency genes OCT4
and NANOG and displayed a high ALP activity (Figures 2(a)
and 2(d)). In diﬀerentiating 10-days EBs, the expression of
OCT4 and NANOG was downregulated, and ALP activity
was diminished (Figures 2(a) and 2(d)). Analysis of CTA
expression has shown that in undiﬀerentiated hES cell lines
SC5, SC7, and SC3a only MAGE-D1, -D2 were expressed at
a high level while other CTA genes were either not expressed
or expressed very weakly (Figure 2(d)).Itis plausiblethatthe
lowlevelofexpressioncouldbeduetofewdiﬀerentiatedcells
which sometimes contaminate undiﬀerentiated cell cultures.
On the other hand, these CTAs may be expressed in both
undiﬀerentiatedandearlydiﬀerentiatedhEScells.IntwohES
cell lines, SC5, and SC7, the expression of MAGE-A3, -A6,
-A4, -A8 and GAGEs was detected in undiﬀerentiated hES
cells and in 10-day EBs formed by these lines. However, the
undiﬀerentiated hES cells and EBs of SC3a line expressed
MAGE-A3,-A6,-A8,andGAGEsbutdidnotexpressMAGE-
A4. The expression of MAGE-A2 and MAGE-B2 was not
detected in any lines studied. In addition, the expression
proﬁle of each hES cell line remained stable during passages
(data not shown).
Nullipotent teratocarcinoma PA-1 cells are the malignant
c o u n t e r p a r to fp l u r i p o t e n ts t e mc e l l st h a tl o s tc o m p l e t e l y
the ability of diﬀerentiation (Figures 2(a) and 2(b)). EC
PA-1 cells and EBs have expressed high level of OCT4 and
NANOG and almost all CTAs studied, MAGE-A2, -A3, -A6,
-A8, MAGE-B2, MAGE-D1, -D2, and GAGE family genes.
Interestingly, like hES SC3a cells, PA-1 cells did not express
MAGE-A4 (Figure 2(d)). Our analysis of hEC PA-1 cells
and hES cells has shown that their CTA expression proﬁles
were very similar, but, at the same time, they diﬀered in the
expression of two CTAs.
3.3. CTA Gene Expression in Diﬀerentiated Human ES Cell
Derivatives. We studied three types of early diﬀerentiated
cell derivatives of human ES SC5 and SC7 cells that
predominated during spontaneous hES cell diﬀerentiation
in vitro. These cells were easily distinguished from other
cells in morphology and could be easily separated from
other cells in cell outgrowths (Figure 3(a)). To identify cell
types, we analyzed speciﬁc gene and protein expression
in the studied samples. The expression of speciﬁc marker
genes for pluripotent (OCT4, NANOG), extraembryonic
endoderm (GATA4, AFP), neuroectodermal (NESTIN) andStem Cells International 5
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Figure 2: CTA expression patterns in hES SC5, SC7, and SC3a cells and hEC PA-1 cells. (a) Activity of alkaline phosphatase and OCT4 in
undiﬀerentiated hES and hEC cells and in EBs formed by these cell lines. Scale bar = 100μm. (b) Histological sections through teratomas
and teratocarcinomas formed by hES and hEC cell lines. Cell derivatives of three germ layers were found in teratomas (TES) formed by hES
cells and entirely cancer cells in teratocarcinomas (TEC). Scale bar = 100μm. (c) Normal diploid karyotypes of hES SC5, SC7, and SC3a
cells: SC5—46, XX; SC7—46, XY; SC3a—46, XX. (d) Expression of CTAs in hES SC5, SC7, and SC3a cells, hEC PA-1 cells and EBs formed
by these cells.
mesenchymal-like (BRY and α-Actinin) cells was tested by
RT-PCR (Figure 3(b)) and immunohistochemical staining
(Figure 3(a)). Analysis of CTA expression in these selected
cellderivativeshasshownthattheextraembryonicendoderm
cells expressing high levels of GATA4 and AFP and low
level of OCT4 express MAGE-A8 and MAGE-D1, -D2 as
well (Figure 3). Mesenchymal-like cells that were α-Actinin
positivebutBRY-negativehadCTAexpressionproﬁlesimilar
to that of extraembryonic endoderm cells (Figure 3). In
contrast, the neuroectodermal cell derivatives expressed
NESTIN and MAGE-A4 (Figure 3). Moreover, all three cell
types expressed MAGE-D1, -D2 genes and did not express
GAGE genes.
3.4. Expression of CTAs in Human Cancer Cell Lines of Neu-
roectodermal and Mesodermal Origin. I no r d e rt od e t e r m i n e
whether CTA-speciﬁc expression patterns were associated
with histological origin or with other characteristics of
t u m o r s ,w et e s t e dc e l ll i n e sw h i c hw e r ed e r i v e df r o m
the embryonic (neuroblastoma, embryonal rhabdomyosar-
coma), childhood (rhabdomyosarcoma, osteosarcoma), and
adult (glioblastoma) cancers of mesodermal and neuroec-
todermal origin. In addition, the expression of OCT4 and
NANOG was studied in all cancer cell lines (Figures 4(a) and
4(b)).
In the neuroblastoma cell lines IMR-32 and SK-N-MC,
CTA expression patterns were markedly diﬀerent. SK-N-
MC cells expressed all MAGEs tested while IMR-32 cells
only two (Figure 4(c)). However, the expression of MAGE-
B2 and diﬀerent levels of MAGE-A8 were detected in both
cell lines. All three glioblastoma cell lines, GL-6, A-172, T-
98G, expressed MAGE-A8 and very weak level of MAGE-
B2. Two of three cell lines, GL-6 and T-98G, expressed
MAGE-A3. Thus, most cancer cell lines from tissues of
neuroectodermal origin expressed MAGE-A8 and MAGE-B2
mRNAs but embryonic tumors (neuroblastomas) expressed
signiﬁcantly higher level of MAGE-B2. The expression of
GAGEs was not detected in any of neuroectodermal cancer
cell lines (Figure 4(c)).
Analysis of CTA expression proﬁles of cancer cell lines
from the tissues of mesodermal origin has shown that all
of them have expressed variable levels of MAGE-A8 and
MAGE-A4. Two lines, embryonal rhabdomyosarcoma RD
and osteosarcoma U-2 OS, had very similar CTA proﬁles,
except MAGEB 2, and expressed almost all CTAs studied
including GAGEs (Figure 4(d)).
As mentioned above, the expression of OCT4, NANOG,
NESTIN, and BRY was tested in cancer cell lines also.
Interestingly, mRNAs of OCT4 and NANOG were detected
by RT-PCR in all cancer lines while the proteins were not
revealed by immunostaining. Likewise, low expression of6 Stem Cells International
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Figure 3: Expression of CTAs and lineage-speciﬁc genes in diﬀerentiated hES cell derivatives. (a) Morphology and immunostaining
of extraembryonic endoderm derivatives by antibodies against GATA4 and OCT4, mesenchymal cells against α-ACTININ and OCT4,
neuroectodermal cells against NESTIN and NANOG. Scale bar = 100μm. (b) Expression proﬁles of CTAs and lineage marker genes in
hES cell derivatives.
BRY has been found at mRNA levels in rhabdomyosarcomas,
andNESTINinneuroblastomasandglioblastomasbutnotat
the protein level (Figure 4, and data not shown). We suggest
that OCT4 and NANOG transcripts detected in all cancer
lines studied may be relevant to the pseudogenes and have
no functional meaning. Similarly, the expression of BRY and
NESTIN at mRNA level may be activated aberrantly in these
cells as often observed in cancer cells.
3.5. CTA Gene Expression Proﬁles in Mouse ES, EG, and EC
C el l sa n di nM o u seG ermL i n eC el l s . The murine Mage genes,
like their human homologues, are expressed in a wide variety
of tumors, in fetal and adult male gonads, and in several
embryonic and extraembryonic tissues [52–57]. In order to
determine whether speciﬁc expression patterns of Mage-a
and Mage-b genes can be attributed to pluripotent stem
cell diﬀerentiation, CTA expression proﬁles were examined
in mouse pluripotent stem cells (ES and EG cells) and
embryonal teratocarcinoma cells (Figures 5(a) and 5(b)).
Moreover, we compared them with the proﬁles of mouse
primordial germ cells at the critical stages of germ line
development: epiblast cells at early gastrulation stage, post-
migratoryprimordialgermcellsjustaftertheiroccupationof
developing genital ridges and gonocytes of male embryonic
gonads. Our results suggest that the pluripotent ES and EG
cells, nullipotent teratocarcinoma EC cells and their EB cells
expressed Mage-a1, 2, 3, 5, 6, 8 and Mage-d1, -d2 but did not
express CTAs of Mage-b family. Furthermore, the expression
of Magea-4 gene was detected in EGC-10 and EC F9 cells but
not in ES R1 cells (Figure 5(b)).
The proﬁles of embryonic germ line cells at the studied
stages were very similar because all CTAs tested, except
Mage-a4, were expressed in all types of germ line cells
(Figure 5(c)). Interestingly, in contrast to other CTAs, Mage-
a 4 was expressed in adult mouse testes but not in the early
primordial germ cells and gonocytes. Thus, the CTA expres-
sion proﬁles of mouse ES, EG, and EC cells signiﬁcantly
diﬀered even from those in the early epiblast cells. On the
other hand, mouse and human embryonic germ line cells
expressed similar CTA families except GAGE antigens which
were not identiﬁed in mice.
4. Discussion
The expression of most CTA genes in the normal tissues
is restricted to adult testicular germ cells but is aberrantlyStem Cells International 7
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activated in various types of cancers. Moreover, CTAs have
b e e nf o u n dt ob ee x p r e s s e di ne m b r y o n i cg e r ma n ds o m a t i c
cells as well as in the extraembryonic structures [29, 50]. We
hypothesizedthatuniqueexpressionpatternofCTAsingerm
cells may be a part of the developmental program which
includes the restriction of germ line from somatic cells dur-
ing the early gastrulation stages. On the other hand, devia-
tions from the normal lineage speciﬁcation can be associated
with disturbances of the typical CTA expression patterns. We
investigated the CTA expression patterns during ES cell dif-
ferentiation in vitro using them as a model of normal lineage
speciﬁcation and compared CTA proﬁles of undiﬀerentiated
ES cells, their diﬀerentiated cell derivatives, and cancer cell
lines of neuroectodermal and mesodermal origin in order to
identify coincident and discriminating gene subsets.
Our results suggest that undiﬀerentiated pluripotent hES
cells expressed low mRNA levels of several CTAs, MAGE-
A3, -A6, -A4, -A8, and GAGEs. Note that MAGE-A4 was
not expressed in hES SC3a cell line that diﬀered from SC5
and SC7 cells in their growth and diﬀerentiation potential
[51].However,unlikeundiﬀerentiatedcells,theearlyhEScell
derivatives expressed only one gene of MAGEA family and
did not express CTAs of GAGE family. It can not be ruled out
that MAGE-A4 and -A8 expression may be referred to both
undiﬀerentiated hES cells and extraembryonic endoderm,
mesenchyme-like and neuroectoderm cells also residing in
EBs whereas MAGE-A3, -A6, and GAGEs were expressed
exclusively in pluripotent cells.
Previously, Gjerstorﬀ et al. [29] also detected MAGE-A2
andMAGE-A6expressioninEBsofKMEB1andKMEB2hES
cell lines and cell derivatives of these lines in teratomas but
not in undiﬀerentiated hES cells. However, only 3 of 6 hES
cell lines studied expressed CTAs during in vitro and in vivo
diﬀerentiation. Moreover, the expression of GAGEs was not
detected either in hES cells or in EBs. In our experiments, the
same primer pairs were used for GAGE expression analysis
but low levels of GAGE 1, 2, 10, 12, 13 transcription were
detected in both undiﬀerentiated hES cells and EBs in all cell
lines studied. Conversely, we did not observe the expression
of MAGE-A2 in any hES cell lines or their diﬀerentiated
cell derivatives but identiﬁed MAGE-A2 mRNA in EC PA-
1 cells. As mentioned above, SC5 and SC7 hES cell lines
had very similar CTA expression proﬁles and similar growth
and diﬀerentiation potentials, and, moreover, each hES cell
line has retained its speciﬁc CTA proﬁle during long-term
cultivation. We suppose that interlinear variations in CTA
expression patterns may be characteristic for a certain hES
cell line state.Stem Cells International 9
Mouse pluripotent ES and EG cells also expressed several
genes of Mage-a family, but, surprisingly, Mage-a4 was
expressed only in mouse EG and EC cells. Furthermore,
the expression of Magea4 was not detected in mouse
primordial germ cells of E 11.5 and E14.5 embryos as well,
although Mage-a4 was expressed in adult male gonads.
Mouse embryonic and adult germ cells also expressed Mage-
b1, 2, 3 genes unlike mouse pluripotent stem cells. Similarly,
the expression of MAGE-B2 was found in adult human testes
but not detected in human ES cells or their cell derivatives.
Thus, the CTA expression proﬁles of mouse ES, EG, and EC
cells signiﬁcantly diﬀered even from the early epiblast cells
as well as from primordial germ cells. Hence, the pluripotent
stem cells in vitro may not be quite equivalent to any of these
cell types in embryos. Nevertheless, the similarity of CTA
expression proﬁles of human and mouse pluripotent stem
cells suggests their similar cell state and origin.
Little is known about CTA expression during the devel-
opment of the germ and somatic lineages in mammals.
Previous studies have shown that during human primordial
germ cell determination, diﬀerentiation, and gonad mat-
uration, the CTA expression patterns undergo signiﬁcant
changes. Firstly, GAGE proteins were expressed in the male
and female primordial and mature germ cells, from 5–
8 weeks of gestation until adulthood [29, 49, 50]. The
expression of MAGE-A1, MAGE-A4, and NY-ESO-1 in
the fetal testes and ovaries is initiated later than GAGE
expression and terminated at diﬀerent development stages
in male and female fetal gonads [47, 48, 50]. MAGE-A4
has been found to be expressed ﬁrstly in single cells of
the fetal testes at the age of 17 weeks, and, thereafter, the
numberofMAGE-A4-positivegonocytesandspermatogonia
progressively increased until 28 weeks. MAGE-A1 and NY-
ESO-1 proteins were also detected in the fetal testes at the
age of 9 weeks and in ovaries at the age of 13 weeks but these
proteins displayed diﬀerential expression patterns through
male and female germ cell development. Our data about
the Mage-a, Mage-b, and Mage-d expression patterns in the
mouse primordial and fetal germ cells also demonstrate for
the ﬁrst time the CTAs implication in an early mouse germ
line development as well as similarities and dissimilarities of
CTA expression patterns in mouse and human embryonic
cells.
Apart from germ cells, the MAGE-A family members
were expressed in somatic lineages, in particular, in human
developing central nervous system and peripheral nerves as
well as in myotome and myoblasts at the early stages (from
5 to 8 weeks) but no MAGE-A expression was detected in
the neural structures of 17- and 23-weeks old fetus or in
the adult brain [29]. Moreover, these authors reported that
GAGE proteins were expressed in the early ectodermal and
neuroectodermal cells but their expression disappeared in
the later diﬀerentiated cells of these lineages. In addition,
MAGE-A protein expression did not correlate with the
GAGE expression pattern in the neuroectodermal cells as
opposed to germ cells. Our ﬁndings that MAGE-A4 and
MAGE-A8 are expressed in the early mesenchymal and
neuroectodermal cells derived from hES cells are consistent
with the previous observations on human fetal tissues and
diﬀerentiated hES cellsin teratomas[29]. On theother hand,
we did not ﬁnd GAGE expression in the above mentioned
diﬀerentiatedcelltypes.Therefore,furtherdetailedexamina-
tion of CTA expression pattern in diﬀerent cell types derived
from pluripotent cells during in vitro diﬀerentiation and in
embryonic tissues can clarify this discrepancy.
The expression of CTAs was also detected in extraem-
bryonic tissues. We identiﬁed MAGE-A8, MAGE-D1, -D2
expression in extraembryonic endoderm cells derived from
hEScells.Previously,inimmunohistochemicalstudyofmore
than50humanplacentasamplesofdiﬀerentgestationalages,
the high level of MAGE-A3 and MAGE-A4 expression was
revealed while the expression of NY-ESO-1 and GAGEs was
sporadic [31]. Genome-wide analysis of CTA expression in
the normal and cancer tissues displayed the MAGE-A 2–
6, 8–11, and XAGE expression in placenta [30]. Human
MAGEL2 gene and its mouse homologue Magel2 were
detected in human and mouse placenta [56]. Taken together,
all these data demonstrate that CTAs are involved in germ
line and somatic lineage development of diﬀerent mammals.
Speciﬁc spatio-temporal patterns of CTAs expression may
be associated with the determination and speciﬁcation of
diﬀerent lineages both in the embryo and during pluripotent
stem cell diﬀerentiation (Figure 6).
Another aspect of our work was the analysis of CTA
expression proﬁles of teratocarcinoma cell lines that are
malignant counterparts of pluripotent stem cells and cancer
cell lines derived from the tissues of neuroectodermal and
mesodermal origin in order to ﬁnd the speciﬁcity of CTA
expression during normal and pathological tissue develop-
ment.Initially,wecomparedCTAproﬁlesofundiﬀerentiated
hES cells, hEC cells, and EBs formed by these cell lines.
The hES and hEC cell CTA proﬁles were very similar, but
hEC cells expressed two additional genes, MAGE-A2 and
MAGE-B2, which were not expressed in the pluripotent stem
cells. Moreover, hEC PA-1 cells did not express MAGE-
A4 like hES SC3a cell line. Interestingly, the CTA proﬁles
studied of mouse ES cells diﬀered from those of mouse EC
cells only in Mage-a4, and, moreover, mouse EC F9 cells
expressed Mage-a4 as opposed to human EC PA-1 cells.
Nevertheless, Mage-a4 was also expressed in the normal
mouse EG cell line. Thus, MAGE-A4/Mage-a4 expression
pattern is variable in murine and human pluripotent and
teratocarcinoma cells, and the question of speciﬁcity of this
expression in pluripotent cells remains open. Recent studies
of normal testes and diﬀerent types of germ cell tumors
have shown that normal spermatogonia and seminoma cells
speciﬁcally expressed MAGE-A4 while anaplastic seminoma
and nonseminoma germ cell tumors were negative for this
antigen [47]. On the other hand, the expression of MAGE-
A2, -A3, -B1, and -B2 was also found in most seminomas
studied while MAGE-A2 and MAGE-A4 were expressed in
pure embryonal carcinoma tumors, as well as in a half
of pure yolk sac tumor samples [33]. In addition, in our
study hEC PA-1cells expressed MAGE-A2 and MAGE-B2
that were not detected in hES cells, and, therefore, these
CTAs may be considered as gene candidates for their further
investigation as early markers of transformed pluripotent
cells.10 Stem Cells International
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Figure 6: CTAs expression in pluripotent cells and derivatives of diﬀerent lineages. Data are summarized from present study (marked by
brown and red) and [29–31, 34, 47–50, 52–57]. Human CTAs are marked with capital letters.
Analysis of CTA expression in the neuroectodermal can-
cer lines has shown that MAGE-A8, MAGE-B2, and MAGE-
A3, -A6 together with MAGE-D1, -D2 are expressed in
most cell lines tested whereas the early neuroectodermal cells
derivedfromhEScellsexpressedonlyMAGE-A4andMAGE-
D1, 2. Thus, no common genes of MAGE-A, MAGE- B, and
GAGE families were revealed in the normal and cancer cells
of this lineage. On the other hand, the frequencies of MAGE-
A1 and MAGE-A3 expression in diﬀerent astrocytomas and
glioblastomas have been demonstrated to vary in range from
0 to 30% [58–60]. Hence, CTA expression patterns in brain
tumors may have low tissue speciﬁcity. Also, we determined
MAGE-A8 and MAGE-A4 as common CTAs in expression
proﬁles of rhabdomyosarcoma and osteosarcoma lines, and
MAGE-A8 was also found in the mesenchymal derivatives
of hES cells. Interestingly, the cancer cell lines of both
neuroectodermal and mesodermal origin expressed MAGE-
A8 while normally it was expressed in the mesenchymal hES
cell derivatives only.
Relatively recently it was found that several CTAs,
includingSSX,NY-ESO-1,andN-RAGE,werealsoexpressed
in undiﬀerentiated mesenchymal stem cells (MSCs) derived
from adult bone marrow or embryonic liver, but their
expression was downregulated after osteocyte and adipocyte
diﬀerentiation [33]. These important data require further
investigations since it is unclear whether CTA expression is
characteristicof MSCs or is activated during their cultivation
in vitro likewise in cancers.
Overall, the frequency of CTA expression is highly
variable among diﬀerent tumor types [28, 30, 60]. For
instance, melanoma, ovarian, liver, and lung cancers are
“CTA-rich” tumors because they have high frequency of CTAStem Cells International 11
expression while hematopoietic, colon, renal, and pancreas
cancershavelowfrequencyofCTAexpression.Moreover,the
cancers of higher histological grade and later clinical stage as
well as metastatic tumors display higher frequency of CTA
expression than the primary tumors. The frequency of CTA
expression correlates with the worst prognosis. Thus, it is
plausible that CTAs are aberrantly activated and expressed in
diﬀerent cancers and have low lineage speciﬁcity. However,
examination and systematization of CTA expression patterns
i ne m b ry o n i ca n da d u l tn o r m a lc e l l sa sw e l la sc a n c e rc e l l so f
diﬀerent types may illuminate whether CTAs are implicated
in normal and pathological lineage development.
5. Conclusions
We have shown that several CTAs, such as MAGE-A3, -A4,
-A6, -A8, and GAGEs, are expressed in the undiﬀerentiated
hEScellsand earlydiﬀerentiated EB cellswhileonly one gene
of MAGE-A family was expressed in the later diﬀerentiated
cell derivatives of hES cells, MAGE-A8 in the extraem-
bryonic endoderm and mesenchymal cells and MAGE-A4
in the neuroectodermal progenitors. Like hES cells, mouse
pluripotent cell lines, ES and EG cells, also expressed CTAs
of Mage-a family but did not express Mage-b family genes
unlike epiblast and primordial germ cells. Moreover, we
detected diﬀerent expression pattern of MAGE-A4/Magea4
in both human and mouse pluripotent and teratocarcinoma
cells. Despite great similarity of CTA expression patterns
in hES and their malignant counterparts, hEC cells, two
of CTAs studied, MAGE-A2 and MAGE-B2, were detected
only in hEC cells but not in hES cells. These CTAs may
be considered as marker gene candidates of transformed
pluripotent cells for further study. Comparative analysis of
CTA proﬁles of cancer cell lines derived from the tissues
of neuroectodermal and mesodermal origin and hES cell-
derivedprogenitorcellsofthesimilarlineageshasshownthat
in most cases CTAs were aberrantly expressed in cancer cells
and display low tissue speciﬁcity. Thus, further investigation
and identiﬁcation of CTA expression patterns in pluripotent
and multipotent stem cells and their derivatives as well
as diﬀerent types of cancers is an important step towards
understanding of CTA functions in normal and cancer cells
and also may be useful for the isolation and removal of
abnormally CTA-expressing cells to improve the safety of
stem cell-based therapy.
Acknowledgments
The authors thank T. M. Nikonova for her assistance in
histological section preparation. They are grateful to Prof. N.
N. Mamaev and Dr. T. L. Gindina (SPb I. P. Pavlov Medical
University) for a possibility to use Ikaros4 Karyotyping
System for transmitted light (MetaSystems, Germany). They
also thank Dr. Sergey Vasetskiy for his critical reading of
the manuscript. This work was supported by the Russian
Foundation for Basic Research, Grant 05-04-49185, 11-04-
00379.
References
[1] M. J. Evans and M. H. Kaufman, “Establishment in culture
of pluripotential cells from mouse embryos,” Nature, vol. 292,
no. 5819, pp. 154–156, 1981.
[ 2 ]Y .M a t s u i ,K .Z s e b o ,a n dB .L .M .H o g a n ,“ D e r i v a t i o no f
pluripotential embryonic stem cells from murine primordial
germ cells in culture,” Cell, vol. 70, no. 5, pp. 841–847, 1992.
[3] M. J. Shamblott, J. Axelman, S. Wang et al., “Derivation of
pluripotent stem cells from cultured human primordial germ
cells,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 95, no. 23, pp. 13726–13731,
1998.
[ 4 ] J .A .T h o m s o n ,J .I t s k o v i t z - E l d o r ,S .S .S h a p i r oe ta l . ,“ E m b r y -
onic stem cell lines derived from human blastocysts,” Science,
vol. 282, no. 5391, pp. 1145–1147, 1998.
[ 5 ]C .A .C o w a n ,J .A t i e n z a ,D .A .M e l t o ne ta l . ,“ N u c l e a rr e p r o -
grammingofsomaticcellsafterfusionwithhumanembryonic
stem cells,” Science, vol. 309, no. 5739, pp. 1369–1373, 2005.
[ 6 ]M .J .M u n s i e ,A .E .M i c h a l s k a ,C .M .O ’ B r i e ne ta l . ,“ I s o l a t i o n
ofpluripotentembryonicstemcellsfromreprogrammedadult
mousesomaticcellnuclei,”Current Biology,vol.10,no.16,pp.
989–992, 2000.
[7] K.TakahashiandS.Yamanaka,“Inductionofpluripotentstem
cells from mouse embryonic and adult ﬁbroblast cultures by
deﬁned factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.
[8] O. Adewumi, B. Aﬂatoonian, L. Ahrlund-Richter et al., “Char-
acterization of human embryonic stem cell lines by the inter-
national stem cell initiative,” Nature Biotechnology, vol. 25, no.
7, pp. 803–816, 2007.
[9] Y. Liu, S. Shin, X. Zeng et al., “Genome wide proﬁling of
human embryonic stem cells (hESCs), their derivatives and
embryonalcarcinomacellstodevelopbaseproﬁlesofU.S.fed-
eral government approved hESC lines,” BMC Developmental
Biology, vol. 6, article 20, 2006.
[10] H. Skottman, M. Mikkola, K. Lundin et al., “Gene expression
signatures of seven individual human embryonic stem cell
lines,” Stem Cells, vol. 23, no. 9, pp. 1343–1356, 2005.
[11] G. Caisander, H. Park, K. Frej et al., “Chromosomal integrity
maintained in ﬁve human embryonic stem cell lines after
prolonged in vitro culture,” Chromosome Research, vol. 14, no.
2, pp. 131–137, 2006.
[12] N. Lavon, K. Narwani, T. Golan-Lev et al., “Derivation
of euploid human embryonic stem cells from aneuploid
embryos,” Stem Cells, vol. 26, no. 7, pp. 1874–1882, 2008.
[13] A. Maitra, D. E. Arking, N. Shivapurkar et al., “Genomic
alterations in cultured human embryonic stem cells,” Nature
Genetics, vol. 37, no. 10, pp. 1099–1103, 2005.
[14] L. V. Sharova, A. A. Sharov, Y. Piao et al., “Global gene ex-
pression proﬁling reveals similarities and diﬀerences among
mouse pluripotent stem cells of diﬀerent origins and strains,”
Developmental Biology, vol. 307, no. 2, pp. 446–459, 2007.
[15] J. Huang, F. Wang, M. Okuka et al., “Association of telomere
length with authentic pluripotency of ES/iPS cells,” Cell
Research, vol. 21, pp. 779–792, 2011.
[16] N. Maherali, R. Sridharan, W. Xie et al., “Directly repro-
grammed ﬁbroblasts show global epigenetic remodeling and
widespread tissue contribution,” Cell Stem Cell,v o l .1 ,n o .1 ,
pp. 55–70, 2007.
[17] K. Okita, T. Ichisaka, and S. Yamanaka, “Generation of
germline-competent induced pluripotent stem cells,” Nature,
vol. 448, no. 7151, pp. 313–317, 2007.
[18] O. Adewumi, B. Aﬂatoonian, L. Ahrlund-Richter et al., “Char-
acterization of human embryonic stem cell lines by the12 Stem Cells International
international stem cell initiative,” Nature Biotechnology, vol.
25, no. 7, pp. 803–816, 2007.
[19] M. H. Chin, M. J. Mason, W. Xie et al., “Induced pluripotent
stem cells and embryonic stem cells are distinguished by gene
expression signatures,” Cell Stem Cell, vol. 5, no. 1, pp. 111–
123, 2009.
[20] M. H. Chin, M. Pellegrini, K. Plath et al., “Molecular analyses
of human induced pluripotent stem cells and embryonic stem
cells,” Cell Stem Cell, vol. 7, pp. 263–269, 2010.
[21] B. Dai and T. P. Rasmussen, “Global epiproteomic signatures
distinguish embryonic stem cells from diﬀerentiated cells,”
Stem Cells, vol. 25, no. 10, pp. 2567–2574, 2007.
[22] M. G. Guenther, G. M. Frampton, F. Soldner et al., “Chro-
matin structure and gene expression programs of human
embryonic and induced pluripotent stem cells,” Cell Stem Cell,
vol. 7, pp. 249–257, 2010.
[23] P. Neveu, M. J. Kye, S. Qi et al., “MicroRNA proﬁling reveals
two distinct p53-related human pluripotent stem cell states,”
Cell Stem Cell, vol. 7, pp. 671–681, 2010.
[24] A.M.NewmanandJ.B.Cooper,“Lab-speciﬁcgeneexpression
signatures in pluripotent stem cells,” Cell Stem Cell, vol. 7, pp.
258–262, 2010.
[25] Y. Mayshar, U. Ben-David, N. Lavon et al., “Identiﬁcation and
classiﬁcation of chromosomal aberrations in human induced
pluripotent stem cells,” Cell Stem Cell, vol. 7, pp. 521–531,
2010.
[26] P. Onyango, S. Jiang, H. Uejima et al., “Monoallelic expression
and methylation of imprinted genes in human and mouse
embryonic germ cell lineages,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 99, no.
16, pp. 10599–10604, 2002.
[27] L. C. Laurent, I. Ulitsky, I. Slavin et al., “Dynamic changes in
the copy number of pluripotency and cell proliferation genes
in human ESCs and iPSCs during reprogramming and time in
culture,” Cell Stem Cell, vol. 8, pp. 106–118, 2011.
[28] O. L. Caballero and Y. Chen, “Cancer/testis (CT) antigens:
potentialtargetsforimmunotherapy,”CancerScience,vol.100,
no. 11, pp. 2014–2021, 2009.
[29] M.F.Gjerstorﬀ,L.Harkness,M.Kassemetal.,“DistinctGAGE
and MAGE-A expression during early human development
indicate speciﬁc roles in lineage diﬀerentiation,” Human
Reproduction, vol. 23, no. 10, pp. 2194–2201, 2008.
[30] O. Hofmann, O. L. Caballero, B. J. Stevenson et al., “Genome-
wide analysis of cancer/testis gene expression,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 105, no. 51, pp. 20422–20427, 2008.
[31] A. A. Jungbluth, W. A. J. Silva, K. Iversen et al., “Expression
of cancer-testis (CT) antigens in placenta,” Cancer Immunity,
vol. 7, p. 15, 2007.
[32] M. Kalejs and J. Erenpreisa, “Cancer/testis antigens and game-
togenesis: a review and “brain-storming” session,” Cancer Cell
International, vol. 5, p. 4, 2005.
[33] T. Yuasa, K. Okamoto, T. Kawakami et al., “Expression
patterns of cancer testis antigens in testicular germ cell tumors
and adjacent testicular tissue,” Journal of Urology, vol. 165, no.
5 I, pp. 1790–1794, 2001.
[34] G. Cronwright, K. Le Blanc, C. G¨ otherstr¨ om et al., “Cancer/
testis antigen expression in human mesenchymal stem cells:
down-regulation of SSX impairs cell migration and matrix
metalloproteinase 2 expression,” Cancer Research, vol. 65, no.
6, pp. 2207–2215, 2005.
[35] S. Laduron, R. Deplus, S. Zhou et al., “MAGE-A1 interacts
with adaptor SKIP and the deacetylase HDAC1 to repress
transcription,” Nucleic Acids Research, vol. 32, no. 14, pp.
4340–4350, 2004.
[36] A. A. Jungbluth, S. Ely, M. DiLiberto et al., “The cancer-testis
antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly
expressed in multiple myeloma and correlate with plasma-cell
proliferation,” Blood, vol. 106, no. 1, pp. 167–174, 2005.
[37] T. Nagao, H. Higashitsuji, K. Nonoguchi et al., “MAGE-A4
interacts with the liver oncoprotein gankyrin and suppresses
its tumorigenic activity,” Journal of Biological Chemistry, vol.
278, no. 12, pp. 10668–10674, 2003.
[38] K. Ohman Forslund and K. Nordqvist, “The melanoma
antigengenes—anycluestotheirfunctionsinnormaltissues?”
Experimental Cell Research, vol. 265, no. 2, pp. 185–194,
2001.
[39] E. Por, H. Byun, E. Lee et al., “The cancer/testis antigen CAGE
with oncogenic potential stimulates cell proliferation by up-
regulating cyclins D1 and E in an AP-1- and E2F-dependent
manner,” Journal of Biological Chemistry, vol. 285, no. 19, pp.
14475–14485, 2010.
[40] L. Marcar, N. J. MacLaine, T. R. Hupp et al., “Mage-A
cancer/testis antigens inhibit p53 function by blocking its
interaction with chromatin,” Cancer Research, vol. 70, no. 24,
pp. 10362–10370, 2010.
[ 4 1 ]J .P a r k ,G .K o n g ,a n dS .L e e ,“ h M A G E - A 1o v e r e x p r e s s i o n
reduces TNF-alpha cytotoxicity in ME-180 cells,” Molecules
and Cells, vol. 14, no. 1, pp. 122–129, 2002.
[42] C. De Smet, C. Lurquin, B. Leth´ e et al., “DNA methylation is
the primary silencing mechanism for a set of germ line- and
tumor-speciﬁc genes with a CpG-rich promoter,” Molecular
and Cellular Biology, vol. 19, no. 11, pp. 7327–7335, 1999.
[43] A. Serrano, A. Garc´ ıa, E. Abril et al., “Methylated CpG points
identiﬁed within MAGE-1 promoter are involved in gene
repression,” International Journal of Cancer,v o l .6 8 ,n o .4 ,p p .
464–470, 1996.
[44] F. Wischnewski, K. Pantel, and H. Schwarzenbach, “Promoter
demethylation and histone acetylation mediate gene expres-
sion of MAGE-A1, -A2, -A3, and -A12 in human cancer cells,”
Molecular Cancer Research, vol. 4, no. 5, pp. 339–349, 2006.
[45] M. J. Scanlan, A. O. Gure, A. A. Jungbluth et al., “Can-
cer/testis antigens: an expanding family of targets for cancer
immunotherapy,” Immunological Reviews, vol. 188, pp. 22–32,
2002.
[46] H. A. Smith and D. G. McNeel, “The SSX family of cancer-
testis antigens as target proteins for tumor therapy,” Clinical
and Developmental Immunology, vol. 2010, Article ID 150591,
2010.
[47] F. Aubry, A. P. Satie, N. Rioux-Leclercq et al., “MAGE-A4,
a germ cell speciﬁc marker, is expressed diﬀerentially in
testicular tumors,” Cancer, vol. 92, no. 11, pp. 2778–2785,
2001.
[48] T. L. Gaskell, A. Esnal, L. L. L. Robinson et al., “Immuno-
histochemical proﬁling of germ cells within the human
fetal testis: identiﬁcation of three subpopulations,” Biology of
Reproduction, vol. 71, no. 6, pp. 2012–2021, 2004.
[49] M. F. Gjerstorﬀ, L. E. Johansen, O. Nielsen et al., “Restriction
of GAGE protein expression to subpopulations of cancer cells
is independent of genotype and may limit the use of GAGE
proteins as targets for cancer immunotherapy,” British Journal
of Cancer, vol. 94, no. 12, pp. 1864–1873, 2006.
[50] M. F. Gjerstorﬀ,K .K o c k ,O .N i e l s e ne ta l . ,“ M A G E - A 1 ,G A G E
andNY-ESO-1cancer/testisantigenexpressionduringhuman
gonadal development,” Human Reproduction,v o l .2 2 ,n o .4 ,
pp. 953–960, 2007.Stem Cells International 13
[51] A. M. Koltsova, O. F. Gordeeva, T. A. Krylova et al., “Com-
partivecharacteristicsofnewhumanembryonicstemcelllines
SC5, SC6, SC7 and SC3a,” Ontogenez, vol. 42, 2011.
[52] T. Aizawa, K. Hasegawa, T. Ohkumo et al., “Neural stem
cell-like gene expression in a mouse ependymoma cell line
transformedbyhumanBKpolyomavirus,”CancerScience,vol.
102, pp. 122–129, 2011.
[53] O. De Backer, A. M. Verheyden, B. Martin et al., “Structure,
chromosomal location, and expression pattern of three mouse
geneshomologoustothehumanMAGEgenes,”Genomics,vol.
28, no. 1, pp. 74–83, 1995.
[54] E. De Plaen, O. De Backer, D. Arnaud et al., “A new family
of mouse genes homologous to the human MAGE genes,”
Genomics, vol. 55, no. 2, pp. 176–184, 1999.
[55] C. ¨ Osterlund, V. T¨ oh¨ onen, K. O. Forslund et al., “Mage-b4, a
novel melanoma antigen (MAGE) gene speciﬁcally expressed
during germ cell diﬀerentiation,” Cancer Research, vol. 60, no.
4, pp. 1054–1061, 2000.
[56] I. Boccaccio, H. Glatt-Deeley, F. Watrin et al., “The human
MAGEL2 gene and its mouse homologue are paternally
expressed and mapped to the Prader-Willi region,” Human
Molecular Genetics, vol. 8, no. 13, pp. 2497–2505, 1999.
[57] T. Aizawa, K. Maruyama, H. Kondo et al., “Expression of
necdin, an embryonal carcinoma-derived nuclear protein, in
developing mouse brain,” Developmental Brain Research, vol.
68, no. 2, pp. 265–274, 1992.
[58] D. D. Chi, R. E. Merchant, R. Rand et al., “Molecular detection
of tumor-associated antigens shared by human cutaneous
melanomas and gliomas,” American Journal of Pathology, vol.
150, no. 6, pp. 2143–2152, 1997.
[59] U. Sahin, M. Koslowski, O. Tureci et al., “Expression of cancer
testis genes in human brain tumors,” Clinical Cancer Research,
vol. 6, no. 10, pp. 3916–3922, 2000.
[60] D. L. Scarcella, C. W. Chow, M. F. Gonzales et al., “Expression
of MAGE and GAGE in high-grade brain tumors: a potential
target for speciﬁc immunotherapy and diagnostic markers,”
Clinical Cancer Research, vol. 5, no. 2, pp. 335–341, 1999.